Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWDDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $791.33M
- Beta
- 0.24
- P/E (TTM)
- 5.6
- EPS (TTM)
- $0.63
Volume 2.22M
Average 2.35M
IRWD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $443K fell 7.5% year over year, behind the +41.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 68.4% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -7.5% toward the trailing-twelve-month pace of +41.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.88M USD
- Year-over-year change
- -6.5%
- 4-year CAGR
- +5.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.88M | -6.5% |
| FY2024 | 2024-12-31 | 2.01M | +27.7% |
| FY2023 | 2023-12-31 | 1.58M | +11.1% |
| FY2022 | 2022-12-31 | 1.42M | -5.5% |
| FY2021 | 2021-12-31 | 1.5M | — |
Depreciation & Amortization vs competitors
How IRWD compares with its peers on the latest reported figures
- IRWD's LTM Mar 2026 depreciation & amortization of $2.79M is the 2nd largest of the 3 companies compared; the peer median is $1.69M.
- Its year-over-year change of +41.0% is the lowest of 2, against a peer median of +51.2%.
- Depreciation & amortization amounts to 0.8% of revenue for IRWD, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.37M | +51.2% | +38.8% | 0.8% | |
| LTM Mar 2026 | $2.79M | +41.0% | +9.9% | 0.8% | |
| LTM Sep 2026 | $0 | — | +72.0% | 0.0% | |
| Peer median (excluding IRWD) | $1.69M | +51.2% | +55.4% | 0.4% | |
Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.45M | 175.07M | (1B) | 880K | 24.02M |
| Depreciation & Amortization | 1.5M | 1.42M | 1.58M | 2.01M | 1.88M |
| Deferred Income Tax | (333.29M) | 65.74M | 72.64M | 68.09M | 40.8M |
| Stock-Based Compensation | 22.28M | 27.05M | 32.01M | 29.85M | 17.25M |
| Change in Working Capital | 17.73M | 2.82M | 11.28M | 739K | 39.65M |
| Accounts Receivables | 7.71M | 7.99M | 924K | 47.24M | 35.15M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.64M) | (8.12M) | 12.38M | (20.21M) | 6.2M |
| Other Working Capital | 12.66M | 2.94M | (2.03M) | (26.29M) | (1.7M) |
| Other Non-Cash Items | 25.23M | 1.67M | 1.07B | 1.98M | 3.45M |
| Operating Cash Flow | 261.9M | 273.76M | 183.43M | 103.55M | 127.04M |
| Capital Expenditures | (265K) | (136K) | (273K) | (142K) | (34K) |
| Acquisitions (Net) | 0 | 0 | (1.03B) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (265K) | (136K) | (1.03B) | (142K) | (34K) |
| Debt Repayment | 0 | (120.7M) | 300M | (115M) | 0 |
| Common Stock Issued | 19.58M | 9.54M | 6.36M | 11.01M | 216K |
| Common Stock Repurchased | (24.13M) | (126.39M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.58M | 9.54M | (29.2M) | (2.98M) | 0 |
| Financing Cash Flow | (4.55M) | (237.55M) | 277.16M | (106.97M) | 216K |
| Effect of Forex Changes | 0 | 0 | (53K) | (32K) | (329K) |
| Net Change in Cash | 257.08M | 36.07M | (565.78M) | (3.6M) | 126.9M |
| Free Cash Flow | 261.63M | 273.63M | 183.15M | 103.41M | 127.01M |
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
Intrinsic Alpha fair value
Locked
Current Price
$4.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.